Tenderwize
Zurück zur Suche

Open-house rebate agreements for Rivaroxaban film-coated tablets excluding 2.5 mg

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Jul 03, 2027 · 309 days left·Open·Supplies·Framework
Registrieren zum SpeichernOpen documents
Originaltitel der Bekanntmachung

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Rivaroxaban Filmtabletten, ausgenommen in der Wirkstärke 2,5 mg, ATC B01AF01

62/100

Opportunity Score

Needs reviewMedium complexity
SuppliesFrameworkOpen
Warum diese Bewertung?

Chance

62 / 100

Komplexität

58 / 100

Risikofaktoren

The notice states the arrangement is an open-house model and not a procurement procedure in the usual sense; legal reme...

Contract documents submitted through the wrong portal area are expressly forbidden; submission must go via the DTVP com...

Tiefe Portfolioanalyse

Tiefe Analyse der Unternehmenspassung

Verwendet:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Überblick

Moderate opportunity

Wichtige Fakten

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Aug 2027
  • Non-exclusive supply/rebate agreement for Rivaroxaban film-coated tablets, excluding 2.5 mg strength.
  • Open-house model with identical, non-individually negotiable contract terms.
Vollständige Zusammenfassung anzeigen

This is an open-house pharmaceutical supply arrangement by AOK Bayern for Rivaroxaban film-coated tablets excluding the 2.5 mg strength (CPV 33600000). It is explicitly described as non-exclusive and non-negotiated, with contracts offered to all interested pharmaceutical companies that meet the stated suitability requirement. The notice includes electronic and paper submission options via DTVP or by post, with strict monthly cut-off rules for contract start dates. No contract value is stated.

Risiken

The notice states the arrangement is an open-house model and not a procurement procedure in the usual sense; legal reme...

Contract documents submitted through the wrong portal area are expressly forbidden; submission must go via the DTVP com...

Analyse kann unvollständig sein

Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.

Wichtige Anforderungen

Eligibility

  • Only pharmaceutical companies are eligible as potential contract partners.

Administrative

  • Signed declaration of reliability (Eigenerklärung zur Zuverlässigkeit) must be submitted.
  • Signed contract and completed annex 'Festlegung der vertragsgegenständlichen Arzneimittel' must be submitted.

Auftraggeber

Ort

München, DEU

Website

www.aok.de

Auftraggeberprofil

Profil öffnen

Kennung

DE811695320

Tätigkeit

Health

Lose (1)

LOT-0001

Open-house rebate agreements for Rivaroxaban film-coated tablets excluding 2.5 mg

Open-house framework-style supply arrangement for Rivaroxaban film-coated tablets, excluding the 2.5 mg strength, for AOK Bayern. The lot description states that contract documents must be submitted via the communication area in the DTVP portal, not via the offer area. The lot is explicitly open to all interested pharmaceutical companies meeting the suitability requirement; information in the notice indicates a maximum of 999 operators may join.

SuppliesFrameworkEU fundedElectronic submission

Ort

DE212, Germany

Dauer

Aug 2025 - Aug 2027

Kategorie

Pharmaceutical products

Frist

Deadline Jul 03, 2027

Vergabedetails

Veröffentlichungsdatum
13 Jul 2025
Sprachen
German

Referenzmetadaten

Rechtsgrundlage
32014L0024

Referenz-IDs

Ausschreibungs-ID
457937-2025

Dokumente (2)

Vergabedokument 1Einreichungsportal 1

Ähnliche Ausschreibungen

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30